Achieve Life Sciences, Inc. Stock price

Equities

ACHV

US0044685008

Biotechnology & Medical Research

Delayed Nasdaq 12:56:25 2024-03-28 pm EDT 5-day change 1st Jan Change
4.545 USD +0.55% Intraday chart for Achieve Life Sciences, Inc. -1.20% +10.32%
Sales 2023 * - Sales 2024 * - Capitalization 95.67M
Net income 2023 * -31M Net income 2024 * -34M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * -
P/E ratio 2023 *
-2.89 x
P/E ratio 2024 *
-3.63 x
Employees 20
Yield 2023 *
-
Yield 2024 *
-
Free-Float 90.72%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.00%
1 week-3.00%
Current month+11.60%
1 month+0.44%
3 months+9.98%
6 months+5.12%
Current year+9.71%
More quotes
1 week
4.47
Extreme 4.47
4.81
1 month
3.89
Extreme 3.89
4.81
Current year
3.75
Extreme 3.75
5.41
1 year
3.03
Extreme 3.03
10.30
3 years
2.00
Extreme 2
11.81
5 years
2.00
Extreme 2
92.60
10 years
2.00
Extreme 2
1 053.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 47 14-07-31
Chairman 65 15-04-30
President 66 08-07-31
Members of the board TitleAgeSince
Director/Board Member 63 22-03-13
Director/Board Member 69 23-03-28
President 66 08-07-31
More insiders
Date Price Change Volume
24-03-28 4.545 +0.55% 83 725
24-03-27 4.52 -3.00% 90,371
24-03-26 4.66 -0.21% 70,140
24-03-25 4.67 +1.52% 91,377
24-03-22 4.6 0.00% 46,633

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Achieve Life Sciences, Inc. is a late-stage clinical pharmaceutical company engaged in the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence. The Company's product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a well-defined, dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline is a partial agonist that binds with high affinity to the alpha-4 beta-2, nicotinic acetylcholine receptors in the brain. Through its dual-acting partial agonist/partial antagonist activity, cytisinicline helps reduce nicotine cravings, withdrawal symptoms and reward and satisfaction associated with smoking. It is developing cytisinicline as an aid to smoking cessation and treatment for nicotine addiction to address the limitations of both prescription drugs and of over-the-counter (OTC) products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
4.52 USD
Average target price
22.57 USD
Spread / Average Target
+399.37%
Consensus
  1. Stock
  2. Equities
  3. Stock Achieve Life Sciences, Inc. - Nasdaq